(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 July 2024 (18.07.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/151554 A3

(51) International Patent Classification:
A61K 35/74 (2015.01) *C07K 16/00* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2024/010754

(22) International Filing Date:
08 January 2024 (08.01.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/479,170	09 January 2023 (09.01.2023)	US
63/487,224	27 February 2023 (27.02.2023)	US
63/487,232	27 February 2023 (27.02.2023)	US

(71) Applicant: **PROTARA THERAPEUTICS, INC.** [US/US]; 345 Park Avenue South, 3rd Floor, New York, New York 10010 (US).

(72) Inventors: **GHIRALDINI, Flavia Gerelli**; c/o Protara Therapeutics, Inc., 345 Park Avenue South, 3rd Floor, New York, New York 10010 (US). **ZUMMO, Jacqueline**; c/o Protara Therapeutics, Inc., 345 Park Avenue South, 3rd Floor, New York, New York 10010 (US). **MAURO, Maurizio**; c/o Protara Therapeutics, Inc., 345 Park Avenue South, 3rd Floor, New York, New York 10010 (US).

(74) Agent: **SUN, Eileen S.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV,

(54) Title: COMBINATION OF NON-VIABLE CELLS OF *STREPTOCOCCUS PYOGENES* AND IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND NON-MUSCLE INVASIVE BLADDER CANCER




FIG. 3B

(57) Abstract: The present disclosure relates to methods of treating triple negative breast cancer or non-muscle invasive bladder cancer in a subject comprising administering to the subject a composition comprising non-viable cells of *Streptococcus pyogenes* and an immune checkpoint inhibitor.

[Continued on next page]

WO 2024/151554 A3

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
29 August 2024 (29.08.2024)